Nitrogen is often the most limiting factor when it comes to crop productivity. A recent three-year study concluded that Pivot Bio’s microbial products effectively deliver nitrogen while delivering ...
SHELTON, CT / ACCESSWIRE / October 9, 2019 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a leader in nanomedicines with novel platform technology to treat difficult and life-threatening ...
Studies compared the change in Packed Cell Volume (PCV), an indicator of increased hematocrit or red blood cell number, from baseline in twenty-three client owned cats with kidney disease; All cats ...
Spear Bio joins collaborative study focused on new biomarkers designed to improve diagnosis of Alzheimer's disease and ...
The Brighterside of News on MSN
New study provides a key breakthrough in cancer therapy and synthetic biology
Randomness inside cells can decide whether a cancer returns after chemotherapy or whether an infection survives antibiotics.
MINNEAPOLIS--(BUSINESS WIRE)--A recently published paper in Radiation Research, the official journal of the Radiation Research Society, details the results from a series of pharmacokinetics (PK) ...
WASHINGTON--(BUSINESS WIRE)--Today, the Biotechnology Innovation Organization (BIO) released the largest ever study of clinical development success rates. The study, conducted in partnership with ...
Bio-Path Holdings, Inc. has announced significant progress with its drug BP1001-A, which has shown potential as a treatment for obesity and Type 2 diabetes in recent preclinical studies. The research ...
The last time I spoke about Tourmaline Bio (TRML) it was with respect to a Seeking Alpha article entitled "Tourmaline Bio: Looking To Go Beyond FcRn Inhibition With IL-6 Targeting." In this article, I ...
WASHINGTON--(BUSINESS WIRE)--Biotechnology Industry Organization (BIO) Industry Analysis and BioMedTracker (BMT) announced results of a study today that shows the overall success rate for drugs moving ...
Upstream Bio, Inc. achieved statistical significance in the phase 2 VIBRANT trial for Verekitug in treating patients with CRSwNP, supporting a Buy rating. Verekitug's once-every-12-weeks dosing offers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback